PTRY(PTRY) - 药物靶点：5T4 x CD3 x PDL1_在研适应症：肿瘤_专利_临床

概要

基本信息

药物类型

多克隆抗体

别名-

靶点

5T4 x CD3 x PDL1

作用机制

5T4抑制剂(5T4滋养层糖蛋白抑制剂)、CD3抑制剂(T细胞表面糖蛋白CD3复合体抑制剂)、PDL1抑制剂(程序性死亡配体1抑制剂)

治疗领域

肿瘤

在研适应症

肿瘤

非在研适应症-

原研机构

Chiome Bioscience, Inc.

在研机构

Chiome Bioscience, Inc.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 PTRY 相关的临床结果

登录后查看更多信息

100 项与 PTRY 相关的转化医学

登录后查看更多信息

100 项与 PTRY 相关的专利（医药）

登录后查看更多信息

1

项与 PTRY 相关的文献（医药）

2016-01-18·Chemistry – A European Journal2区 · 化学

Direct Assembly of Mesoporous Silica Functionalized with Polypeptides for Efficient Dye Adsorption

2区 · 化学

Article

作者: Yamauchi, Yusuke ; Bastakoti, Bishnu Prasad ; Kuo, Shiao‐Wei ; Pramanik, Malay ; Lu, Yi‐Syuan ; Malgras, Victor

AbstractHerein, we introduce a new polypeptide‐functionalized mesoporous silica template fabricated from a biodegradable poly(ethylene oxide‐b‐ɛ‐caprolactone) (PEO‐b‐PCL) diblock copolymer and a poly(tyrosine) (PTyr) biopolymer. The crystallization behavior of the PEO‐b‐PCL diblock copolymer changes after blending, but the secondary structure of PTry remains stable. After selective solvent extraction in THF, the PEO‐b‐PCL is removed, but PTyr remains within the silica matrix due to its different solubility. Fourier‐transform IR spectroscopic analysis (FTIR), thermal gravitometry analysis (TGA), small‐angle X‐ray scattering (SAXS), and X‐ray diffraction (XRD) studies confirm the retention of PTyr to form a polypeptide‐functionalized mesoporous material. The adsorption of methylene blue hydrate (MB) from aqueous solution into the polypeptide‐functionalized mesoporous silica is investigated, thus revealing that the nanocomposite exhibits a high adsorption capacity relative to pure silica due to hydrogen‐bonding interactions between the hydroxy phenolic group of PTyr and the N‐containing aromatic ring from MB.

100 项与 PTRY 相关的药物交易

登录后查看更多信息